BRAF Mutations: Oncogenic Drivers in Solid Tumors

Abstract excerpt

From their discovery in 2002, BRAF mutations have been identified as clear drivers of oncogenesis in several cancer types. Currently, their incidence rate is nearly 7% of all solid tumors with BRAF V600E constituting approximately 90% of these diagnoses [1]. In melanoma, thyroid cancer, and histiocytic neoplasms, BRAF hotspot mutations are found at a rate of about 50%, while in lung and colorectal cancers they ran...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Cancer Genomics and Diagnostics
• Clinical Decision-Making
• Colorectal Cancer Treatments and Studies
• Melanoma and MAPK Pathways
• Molecular Targeted Therapy
• Mutation Rate
• Proto-Oncogene Proteins B-raf

Identifiers and source

Literature Corpus work

cca968df-7dcd-5107-9513-148b9bf471b4

DOI

10.20944/preprints202401.1957.v2